Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bulleyaconitine A in preparation of drugs for treating irritable bowel syndrome

A technology for irritable bowel syndrome and fenugreek, which is applied in the field of biomedicine, can solve the problems of increasing constipation intractability, drug dependence, and no effective drugs, and achieves expanded indications, high safety, safety and effectiveness. The effect of drug choice

Active Publication Date: 2019-05-07
SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT) +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, many drugs for the treatment of IBS on the market have adverse reactions. For example, although anticholinergic drugs can relieve abdominal pain and stop diarrhea, they can easily cause abdominal distension, and long-term use will lead to drug dependence, which will increase the intractability of constipation
For the relief of abdominal pain symptoms and psychogenic symptoms such as anxiety, there is no effective drug or optional combination drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bulleyaconitine A in preparation of drugs for treating irritable bowel syndrome
  • Application of bulleyaconitine A in preparation of drugs for treating irritable bowel syndrome
  • Application of bulleyaconitine A in preparation of drugs for treating irritable bowel syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: The effect of orientalin on anti-anxiety, pain sensitivity and visceral pain caused by IBS.

[0019] 1. Experimental animals:

[0020] IBS can be divided into constipation type (IBS-C), diarrhea type (IBS-D), indeterminate type (IBS-U) and mixed type (IBS-M), and IBS-D is the most common type. In order to simulate a more suitable clinical pathogenesis and the most common IBS animal model, the present invention combines five heterologous chronic stress simulated IBS rat models on the basis of neonatal enteritis, which is equivalent to the IBS postinflammation (IBS-PI) model, and detects large Effects on visceral sensitivity, changes in mental activity, feces score, and the number of defecated pellets in rats. In the experiment, female SD rats, which are more prone to IBS symptoms, were used for the experiment. SD rats were bred and raised in the Department of Experimental Animal Science and the Central Key Laboratory of Shanghai Jiaotong University. The feed...

Embodiment 2

[0044] Effects of sativa on intestinal defecation habit and gastrointestinal motility function in SD rats with chronic visceral pain.

[0045] Because females in infancy are prone to stress and anxiety symptoms, the inventor divided female SD rats into experimental groups (two groups) and control groups. The weight of SD rats was 80 ± 2 to 100 ± 2g, and there were ten rats in each group. . The experimental process is as follows Figure 7 As shown in A, the SD rats in the experimental group and the control group underwent colonic perfusion with 2,4,6-trinitrobenzenesulfonic acid 10 days after birth. When the rats were 3 weeks old (the SD rats in this age group were in juvenile to adolescence), the experimental group was administered gavage with aconitin (two administration concentrations: 0.3mg / kg, 0.9mg / kg; 10ml / kg / day), the control group was given the same volume of normal saline / day. Then SD rats in the experimental group and the control group were restrained in a fix...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention belongs to the field of biomedicine and discloses a new application of bulleyaconitine A in preparation of drugs for treating irritable bowel syndrome. When the bulleyaconitine Ais applied to the treatment of the irritable bowel syndrome, the bulleyaconitine A can effectively alleviate visceral pain, mental anxiety and hyperalgesia caused by the irritable bowel syndrome, andis safe and effective.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of aconitin in the preparation of medicines for treating irritable bowel syndrome (IBS). Background technique [0002] Irritable bowel syndrome (IBS) is defined as recurrent symptoms of visceral pain or a syndrome associated with altered bowel habits, characterized by abdominal pain, bloating, diarrhea, or constipation, of unknown etiology. IBS is the most common type of functional gastrointestinal disorder, and its clinical manifestations are mainly manifested in chronic abdominal intermittent or persistent hyperalgesia, changes in bowel emptying habits, and often accompanied by symptoms of anxiety. Emotional factors, diet, drugs, or hormones can trigger or exacerbate this high-tonic GI motility. Some IBS patients have anxiety disorders, especially phobias, adult depression, and somatic symptomatization disorders. Currently, there is no clear and effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P1/00A61P29/00A61P25/22
Inventor 陈京红王永祥鞠培俊黄胜男
Owner SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com